ST
ATRA icon

Smithfield Trust’s Atara Biotherapeutics ATRA Stock Holding History

Smithfield Trust’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-29
Closed -$6K – 1056
2022
Q2 		$6K Hold
29
– – ﹤0.01% 913
2022
Q1 		$7K Hold
29
– – ﹤0.01% 903
2021
Q4 		$12K Hold
29
– – ﹤0.01% 809
2021
Q3 		$13K Hold
29
– – ﹤0.01% 781
2021
Q2 		$11K Hold
29
– – ﹤0.01% 801
2021
Q1 		$10K Buy
29
+7
+32% +$3.09K ﹤0.01% 830
2020
Q4 		$11K Buy
22
+8
+57% +$3.69K ﹤0.01% 788
2020
Q3 		$5K Hold
14
– – ﹤0.01% 913
2020
Q2 		$5K Buy
14
+7
+100% +$1.77K ﹤0.01% 843
2020
Q1 		$2K Hold
7
– – ﹤0.01% 872
2019
Q4 		$3K Hold
7
– – ﹤0.01% 854
2019
Q3 		$3K Hold
7
– – ﹤0.01% 891
2019
Q2 		$4K Hold
7
– – ﹤0.01% 827
2019
Q1 		$7K Hold
7
– – ﹤0.01% 709
2018
Q4 		$6K Buy
+7
New +$6.5K ﹤0.01% 716

Other funds holding ATRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Smithfield Trust's ATRA Position: Q3 2022 in Review

Smithfield Trust sold out of Atara Biotherapeutics (ATRA) in Q3 2022, closing a stake of 29 shares — an estimated $6K sold.

Smithfield Trust first reported a position in ATRA in Q4 2018 and held it in 15 quarters. The position peaked at $13K in Q3 2021. 154 funds tracked by Wall St. Rank hold ATRA as of Q3 2022.

  • Smithfield Trust reported no remaining Atara Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Smithfield Trust sold 29 Atara Biotherapeutics shares in Q3 2022, an estimated $6K.
  • Smithfield Trust first reported a position in Atara Biotherapeutics in Q4 2018 and held it in 15 quarters.
  • Smithfield Trust's Atara Biotherapeutics position peaked at $13K in Q3 2021.
  • 154 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2022.

Based on Smithfield Trust's 13F filing for Q3 2022, filed 14 Nov 2022.